Global Wearable Medical Devices Market is valued at approximately USD 59.12 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 28.6% during the forecast period ...

Biocon Biologics delivers 100 million insulin cartridges to Malaysia, commercializes biosimilars in key global markets with ...

Supplies over 100 million cartridges of recombinant human insulin to Malaysia's Ministry of Health ...

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BS ...

Biocon Biologics receives Health Canada approval for its biosimilar Yesafili injection, used to treat various eye ailments.

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...